Abstracts tagged "autoimmune diseases and rituximab"

Abstract Number: 1343 • 2016 ACR/ARHP Annual Meeting
Efficacy of Biological-Targeted Treatments in MDS-Related Systemic Autoimmune Diseases: Multicenter Retrospective Study of 28 Patients
Guillaume Dervin¹, Arsène Mékinian², Jean-Emmanuel Kahn³, louis Terriou⁴, Eric Liozon⁵, Eric Grignano⁶, odile beyne Rauzy⁷, Pascal Godmer⁸, Julien Rossignol⁹, Geraldine Falgarone¹⁰, Laurence Bouillet¹¹, Achille Aouba¹², Philippe Guilpain¹³, David Launay¹⁴, jonathan Broner¹⁵, jerome gillard¹⁶, lionel ades¹⁷, clemence salvado¹⁸, thierry cardon¹⁹, Jean-Charles Piette²⁰, Pierre Fenaux²¹ and Olivier Fain², ¹Medecine Interne Hopital Saint antoine, Paris, France, ²Service de médecine interne. Hôpital Saint-Antoine., Paris, France, ³Internal Medicine, Foch Hospital, Suresnes, France, ⁴médecine interne CHRU lille, Lille, France, ⁵Departement of Internal Medicine, Limoges University Hospital, Limoges, France, ⁶Internal Medicine, DHUi2B Saint Antoine Hospital, paris, France, ⁷Medecine interne CHU Purpan, toulouse, France, ⁸CH Vannes, Vannes, France, ⁹haematology, paris, France, ¹⁰Medecine Interne Hopital Avicenne, Bobigny, France, ¹¹CHU, Grenoble, France, ¹²Medecine Interne Hopital Necker, Paris, France, ¹³Medecine interne CHU Montpellier, Montpellier, France, ¹⁴Service de Médecine Interne, Centre National de Référence des Maladies Systémiques Rares, Hôpital Claude Huriez, CHRU Lille, Lille, France, ¹⁵Medecine Interne CHRU Montpellier, Montpellier, France, ¹⁶Medecine Interne CHRU Lons le Saunier, Lons, France, ¹⁷Service Hématologie Hopital d'Avicennes, Bobigny, France, ¹⁸Service d'hématologie CHU Mondor, Creteil, France, ¹⁹Medecine interne CHU Lille, lille, France, ²⁰Internal Medicine, Pitié-Salpêtrière University Hospital, Paris, France, ²¹Hematologie Hopital Avicenne, Bobigny, France
Background/Purpose: This study analyze the safety and efficiency of biologics (TNF-α antagonists, tocilizumab, rituximab and IL-1 inhibitors) in patients with autoimmune systemic diseases (SAIDs) associated…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].